Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2018 11:22 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Addresses Maryland Attorney General’s Motion

PHOENIX, Feb. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
February 01, 2018 23:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Addresses New York Attorney General’s Complaint

PHOENIX, Feb. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
February 01, 2018 09:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Appoints Vaseem Mahboob to Board of Directors

PHOENIX, Feb. 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology,...
January 30, 2018 09:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Adds Two New Executives to Senior Management Team

VP of Human Resources, Carol Summersgill; VP of Clinical Development, Dr. Ahmed Elkashef PHOENIX, Jan. 30, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the...
January 03, 2018 09:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics to Present at J.P. Morgan Healthcare Conference

PHOENIX, Jan. 03, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that Saeed Motahari, president and chief executive officer, and Andrew Long, chief financial...
December 26, 2017 08:30 ET | Source: Insys Therapeutics, Inc.

FDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as Investigational Treatment for Prader-Willi Syndrome

PHOENIX, Dec. 26, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the...
December 19, 2017 08:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) Oral Solution for Treatment of Refractory Childhood Absence Epilepsy in Pediatric Patients

PHOENIX, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Can a synthetic formulation of cannabidiol (CBD), one of the main molecules in cannabis, safely help control treatment-resistant “staring” seizures in...
December 07, 2017 09:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics Starts Proof-of-Concept Study of Epinephrine Nasal Spray for Anaphylaxis

PHOENIX, Dec. 07, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that it has started a proof-of-concept study of two formulations of...
December 06, 2017 09:37 ET | Source: Insys Therapeutics, Inc.

FDA Accepts New Drug Application (NDA) for Buprenorphine Sublingual Spray from INSYS Therapeutics

PHOENIX, Dec. 06, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), announced today that its New Drug Application (NDA) for a novel formulation of...
November 27, 2017 06:00 ET | Source: Insys Therapeutics, Inc.

INSYS Therapeutics, Inc. to Participate in the 29th Annual Piper Jaffray Healthcare Conference

PHOENIX, Nov. 27, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”) announced today that Saeed Motahari, president and chief executive officer, and Andrew...